US EditionCanadian scientist wins Breakthrough Prize for discovery of hormone used in Ozempic, Mounjaro
- Danielle Griffin, a 38-year-old from New Mexico, struggled with GLP-1 drugs for weight loss, losing only 13 pounds before plateauing, according to her account.
- Dr. Marc Bessler from Northwell Lenox Hill Hospital highlighted that there is no universal solution for obesity treatment, emphasizing the complexity of the disease.
- Dr. Stephen Hauser from UC San Francisco received a Breakthrough Prize for his research that revolutionized the understanding of Multiple Sclerosis, revealing that B-type white blood cells are a major cause of neurological damage.
- Approximately 30 million Americans have tried GLP-1 weight loss medications like Ozempic and Wegovy, despite varying success rates and concerns about side effects, according to Columbia University.
35 Articles
35 Articles
Ozempic didn’t work for me
Doctors say it’s not uncommon for patients to not lose weight on the GLP-1 drugs, even if celebrities are seemingly shedding dozens of pounds. Julia Musto spoke to people frustrated that they are part of the 20 percent of people who don’t have success
Rising cost of weight-loss drugs has state Medicaid programs looking for solution
Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the budgetary squeeze from fast-rising costs
Global News
Canadian scientist wins Breakthrough Prize for discovery of hormone used in Ozempic, Mounjaro
A Canadian scientist has won a 2025 Breakthrough Prize in Life Sciences for discovering a hormone used in diabetes and obesity medications that has changed the lives of millions.
Coverage Details
Bias Distribution
- 68% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
